Literature DB >> 10744365

In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus.

I You1, R Kariyama, M J Zervos, H Kumon, J W Chow.   

Abstract

In-vitro susceptibility studies were performed on 99 clinical Staphylococcus aureus isolates. A total of 68 of 73 methicillin-resistant S. aureus and 2 of 26 methicillin-susceptible S. aureus were gentamicin-resistant (gentamicin MIC range 16 to 1,024 microg/mL). All 70 gentamicin-resistant isolates contained the aac(6')-Ie-aph(2'')-Ia aminoglycoside resistance gene, and none possessed the aph(2'')-Ic or aph(2'')-Id aminoglycoside resistance genes. The arbekacin MIC for the 70 gentamicin-resistant isolates ranged from 0.25 to 4 microg/mL. The combination of arbekacin plus vancomycin produced synergistic killing against 12 of 13 gentamicin-resistant MRSA isolates. The combination of gentamicin plus vancomycin produced synergistic killing against 7 of the same 13 isolates. Arbekacin may prove useful when used in combination with vancomycin in treating infections caused by gentamicin-resistant MRSA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744365     DOI: 10.1016/s0732-8893(99)00104-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  11 in total

1.  Simple and reliable multiplex PCR assay for surveillance isolates of vancomycin-resistant enterococci.

Authors:  R Kariyama; R Mitsuhata; J W Chow; D B Clewell; H Kumon
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

2.  Detection of the high-level aminoglycoside resistance gene aph(2")-Ib in Enterococcus faecium.

Authors:  S J Kao; I You; D B Clewell; S M Donabedian; M J Zervos; J Petrin; K J Shaw; J W Chow
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  Vanthida Huang; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance.

Authors:  V Kak; S M Donabedian; M J Zervos; R Kariyama; H Kumon; J W Chow
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Synergy of arbekacin-based combinations against vancomycin hetero-intermediate Staphylococcus aureus.

Authors:  Ji Young Lee; Won Sup Oh; Kwan Soo Ko; Sang Taek Heo; Chi Sook Moon; Hyun Kyun Ki; Sungmin Kiem; Kyong Ran Peck; Jae Hoon Song
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

Review 6.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

7.  Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model.

Authors:  Dong-Gun Lee; Hye-Sun Chun; Dong-Seok Yim; Su-Mi Choi; Jung-Hyun Choi; Jin-Hong Yoo; Wan-Shik Shin; Moon-Won Kang
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

8.  Aminoglycoside-resistance mechanisms in multidrug-resistant Staphylococcus aureus clinical isolates.

Authors:  R Kelmani Chandrakanth; S Raju; S A Patil
Journal:  Curr Microbiol       Date:  2008-03-05       Impact factor: 2.188

9.  Virulence and the presence of aminoglycoside resistance genes of Staphylococcus haemolyticus strains isolated from clinical specimens.

Authors:  Sylwia Krzymińska; Ewa Szczuka; Kinga Dudzińska; Adam Kaznowski
Journal:  Antonie Van Leeuwenhoek       Date:  2015-01-15       Impact factor: 2.271

10.  Multicomponent therapeutics of berberine alkaloids.

Authors:  Jiaoyang Luo; Dan Yan; Meihua Yang; Xiaoping Dong; Xiaohe Xiao
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.